WST — West Pharmaceutical Services Income Statement
0.000.00%
- $15.51bn
- $15.23bn
- $2.89bn
- 93
- 15
- 64
- 59
Annual income statement for West Pharmaceutical Services, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,147 | 2,832 | 2,887 | 2,950 | 2,893 |
Cost of Revenue | |||||
Gross Profit | 768 | 1,178 | 1,136 | 1,129 | 999 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,740 | 2,081 | 2,205 | 2,270 | 2,323 |
Operating Profit | 407 | 751 | 682 | 680 | 570 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 401 | 749 | 680 | 698 | 586 |
Provision for Income Taxes | |||||
Net Income After Taxes | 329 | 640 | 560 | 576 | 478 |
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 346 | 662 | 586 | 593 | 493 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 346 | 662 | 586 | 593 | 493 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4.7 | 8.75 | 8.4 | 8.15 | 6.82 |
Dividends per Share |